60 Degrees Pharma Files NDIN for Australian Chestnut Extract

60 Degrees Pharmaceuticals has officially entered the New Dietary Ingredient (NDI) notification process with the U.S. Food and Drug Administration, filing documentation on March 18, 2026, for Australian Chestnut Extract as a dietary supplement ingredient. The submission marks a noteworthy example of pharmaceutical companies increasingly participating in the dietary supplement marketplace, where regulatory pathways differ significantly from traditional drug development.

The FDA now has until May 25, 2026—a standard 75-day review period—to raise objections to the notification. If no concerns are identified during this window, 60 Degrees Pharmaceuticals will be positioned to commercialize dietary supplements containing the botanical extract, which the company has also secured in a specialized FSU capsule formulation.

Understanding the NDI Notification Pathway

The New Dietary Ingredient notification process represents a critical regulatory gateway for companies introducing novel ingredients to the U.S. supplement market. Under the Dietary Supplement Health and Education Act of 1994 (DSHEA), any dietary ingredient not marketed in the United States before October 15, 1994, must undergo NDI notification before being legally sold as a supplement.

This regulatory framework differs fundamentally from the pharmaceutical approval process. Rather than requiring premarket approval with extensive clinical trials, the NDI pathway places the burden on manufacturers to demonstrate that their ingredient is reasonably expected to be safe under its intended conditions of use. Key elements of a successful NDIN submission typically include:

• Comprehensive identity and composition data for the ingredient
• Manufacturing processes and quality control measures
• Historical evidence of safe use or toxicological data
• Recommended dosage levels and target populations
• Literature review supporting safety under intended use conditions

According to FDA data, the agency receives approximately 50-80 NDI notifications annually, with roughly 30-40% resulting in acknowledgment letters indicating no objection. The remaining notifications often face questions about safety evidence, ingredient characterization, or manufacturing specifications.

Australian Chestnut Extract: A Novel Botanical Entry

Australian Chestnut Extract represents an intriguing addition to the botanical supplement category, which has experienced sustained growth as consumers increasingly seek plant-based wellness solutions. The extract derives from Castanospermum australe, a tree native to the rainforests of eastern Australia, traditionally known among indigenous populations for various ethnobotanical applications.

While 60 Degrees Pharmaceuticals has not publicly disclosed the specific bioactive compounds or intended health benefits associated with their Australian Chestnut Extract formulation, botanical extracts from this genus have previously attracted scientific interest for their unique phytochemical profiles. The company's decision to pursue FSU (fast-dissolving or specialized-release) capsule technology suggests a focus on optimizing bioavailability and consumer experience.

The intersection of pharmaceutical expertise and dietary supplement development often brings enhanced quality control, standardization practices, and research capabilities to the supplement sector. Companies with pharmaceutical backgrounds typically employ more rigorous analytical testing, stability studies, and manufacturing protocols than traditionally seen in the supplement industry.

Industry Context and Market Implications

The filing comes amid broader trends reshaping the dietary supplement landscape. Pharmaceutical and biotech companies are increasingly viewing the supplement market as a strategic opportunity, particularly as consumers demonstrate growing interest in preventive health measures and natural products. The global dietary supplements market, valued at over $150 billion annually, continues expanding at approximately 8-9% yearly growth rates.

Industry analysts note that successful NDI notifications can provide competitive advantages, as they demonstrate regulatory compliance and may serve as barriers to entry for competitors seeking to market similar ingredients. For smaller pharmaceutical companies like 60 Degrees Pharmaceuticals, the supplement pathway offers a potentially faster route to market compared to traditional drug development, which typically requires 10-15 years and costs exceeding $1 billion.

Before purchasing any dietary supplement, consumers should verify products through resources like the PharmoniQ Supplement Checker, which provides independent analysis of supplement formulations, safety profiles, and regulatory status.

What Happens Next: The 75-Day Window

During the review period ending May 25, 2026, FDA scientists will evaluate whether the submitted safety data adequately supports the intended use of Australian Chestnut Extract. The agency may request additional information, issue a letter indicating it has no objections, or formally object if safety concerns are identified.

If FDA raises no objections by the deadline, 60 Degrees Pharmaceuticals can proceed with marketing supplements containing the ingredient. However, the absence of an objection letter does not constitute FDA approval or endorsement—it simply means the agency did not identify immediate safety concerns warranting further action during its initial review.

The company will still bear responsibility for ensuring its products are safe, properly labeled, and manufactured according to Current Good Manufacturing Practices (cGMP) for dietary supplements. Post-market surveillance by FDA continues regardless of NDI notification status, and the agency retains authority to take action against products found to be unsafe or misbranded.

Looking Ahead: Pharma-Supplement Convergence

The 60 Degrees Pharmaceuticals filing exemplifies an ongoing convergence between pharmaceutical rigor and dietary supplement innovation. As more companies with drug development expertise enter the supplement space, consumers may benefit from enhanced product quality, better-characterized ingredients, and more robust safety data.

For the broader industry, successful navigation of the NDI pathway by pharmaceutical companies may set precedents for scientific standards and documentation expectations. The outcome of this notification, along with subsequent market performance if approved, will likely inform strategic decisions by other pharma companies evaluating whether to develop dietary supplement portfolios.

Industry observers will be watching closely as the May 25 deadline approaches, both for implications regarding this specific ingredient and for broader insights into FDA's current approach to novel botanical extracts in the evolving supplement regulatory landscape.